Valuation: GlaxoSmithKline Pakistan Limited

Market Cap 118B 424M 371M 343M 320M 602M 40.11B 613M 4.11B 1.6B 19.79B 1.59B 1.56B 68.95B P/E 2026 *
10.7x
P/E 2027 * 9.17x
Enterprise Value 118B 424M 371M 343M 320M 602M 40.11B 613M 4.11B 1.6B 19.79B 1.59B 1.56B 68.95B EV / Sales 2026 *
1.71x
EV / Sales 2027 * 1.58x
Free-Float
16.89%
Yield 2026 *
5.01%
Yield 2027 * 5.62%
08/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
08/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
01/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
30/04 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
30/04 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
27/04 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
09/04 GlaxoSmithKline Pakistan Limited Proposes Final Cash Dividend for the Financial Year Ended 31 December 2025 CI
07/04 GlaxoSmithKline Pakistan Limited Announces Board Changes CI
31/03 GlaxoSmithKline Pakistan Limited Announces Resignation of Lai Kuen Goh as Chairperson and Non-Executive Director, with Effect from March 31, 2026 CI
26/03 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25/10/25 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
02/09/25 GlaxoSmithKline Pakistan Limited Declares Interim Cash Dividend for the Half Year Ended June 30, 2025 CI
26/08/25 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
1 day+1.66%
1 week+1.94%
Current month+4.36%
1 month+4.36%
3 months+15.67%
6 months-4.41%
Current year-5.01%
1 week 359.5
Extreme 359.5
373
1 month 343
Extreme 343
384.2
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.94
3 years 68
Extreme 68
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 01/03/2020
Director of Finance/CFO - 01/06/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 07/05/2011
Director/Board Member - 05/12/2018
Director/Board Member 72 02/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.66%+1.94%-5.16%+391.24% 417M
-1.63%+9.30%+55.23%+158.02% 1,097B
-1.16%+6.99%+67.46%+54.54% 622B
-0.65%+7.80%+36.34%+87.83% 449B
-1.62%+6.34%+29.51%+24.01% 334B
-1.38%+3.75%+39.33%+25.04% 294B
+0.30%+2.56%+31.62%+40.64% 286B
-0.10%+2.23%-28.43%-42.77% 213B
-0.12%+3.79%+29.07%+62.32% 195B
-0.49%+0.58%+13.45%+63.20% 157B
Average -0.44%+6.30%+26.84%+86.41% 364.72B
Weighted average by Cap. -0.97%+8.72%+41.41%+78.64%

Financials

2026 *2027 *
Net sales 68.81B 248M 217M 200M 187M 352M 23.41B 358M 2.4B 931M 11.55B 930M 909M 40.24B 74.58B 268M 235M 217M 202M 381M 25.37B 388M 2.6B 1.01B 12.52B 1.01B 985M 43.61B
Net income 10.49B 37.74M 33.03M 30.49M 28.44M 53.59M 3.57B 54.55M 366M 142M 1.76B 142M 139M 6.13B 12.42B 44.68M 39.11M 36.1M 33.68M 63.45M 4.22B 64.58M 433M 168M 2.08B 168M 164M 7.26B
Net Debt - -
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
30/06/26 PKR 370.25 +1.66% 396,486
29/06/26 PKR 364.22 -0.73% 309,601
24/06/26 PKR 366.89 +2.14% 211,025
23/06/26 PKR 359.21 -1.10% 254,984
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
370.25PKR
Average target price
517.50PKR
Spread / Average Target
+39.77%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock